Anti-Viral Therapies Market to Grow at a CAGR of 8.3% to reach US$ 76,282.63 Million from 2020 to 2027

Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type (Generic Drugs, Branded Drugs); Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, Others); Application (HIV, Hepatitis, Virus Influenza, Herpes, Other Applications) and Geography

Publication Month: Aug 2020 | Report Code: TIPRE00012650 | No. of Pages: 170 | Category: Pharmaceuticals | Status: Published
Covid

The anti - viral therapies market is expected to reach US$ 76,282.63 million by 2027 from US$ 40,589.79 million in 2019; the market is estimated to grow at a CAGR of 8.3% from 2020 to 2027.

Antiviral therapy is one of the most exciting branches of virology. It entails several strategies used to develop antiviral therapy, including direct-acting antivirals that target viral proteins, enzymes, or nucleic acids; passive antibodies that neutralize viruses circulating in drug; and drugs that target cellular proteins or processes essential for viral replication.The global anti - viral therapies market is driven by factors such as increasing R&D expenditures by pharmaceutical companies, and rising government support for research activities and clinical trials. However, the high cost of drug development may hinder the market growth. Additionally, emerging markets are creating growth opportunities for the market players.

 

Lucrative Regional Markets for Anti - Viral Therapies

Lucrative Regional Markets for Anti - Viral Therapies

Get more information on this report :



Market Insights

Rising Government Support for Research Activities and Clinical Trials

The clinical trials industry has seen exceptional growth in the last 10 years. In August 2019, the US Food and Drug Administration (USFDA) revealed that it awarded 12 new clinical trial research grants of more than US$ 15 million in total, for the period 2020–2023, to improve the development of medical products for patients with rare diseases. The grants were conferred to principal investigators from industry and academics across the country. The FDA awarded the grants through the Orphan Products Clinical Trials Grants Program, which is funded by Congress to promote the clinical development of medical foods, biologics, drugs, and medical devices for the treatment of rare diseases. The grants are intended to considerably contribute to the marketing approval of products to treat rare diseases and provide essential data for the development of such products. For clinical trials of possibly life-changing treatments for patients with rare diseases, the FDA has been offering much-needed financial support for more than 35 years. In addition, the Orphan Products Clinical Trials Grants Program’s contributions have supported research that will led to the marketing approval of treatments for rare diseases.

COVID-19 vaccine development has attained high pace due to large number of participants focusing on clinical trials and collaborations to make certain rapid growth and sufficient production capacity. In addition, the UK government has committed to provide US$ 99.9 million (£84 million) in funding and manufacturing support to researchers to work on this vaccine program. Further, the US government has agreed to fund US$ 483 million for Moderna Inc. to develop and test its COVID-19 vaccine, which is currently in an initial clinical trial. The biotech industry in Europe is playing a vital part in the fight against COVID-19, in terms of developing vaccines, therapeutic drugs, diagnostics, and research. For instance, the European Commission offered US$ 105.8 million (EUR 89 million) to CureVac for the development of COVID-19 vaccine, in March 2020.

Such significant funding initiatives by governments for encouraging research activities and clinical trials are boosting the growth of the anti-viral therapies market.

 

Type-Based Insights

The anti-viral therapies market, by type, is segmented into generic drugs and branded drugs. The branded drugs segment held a larger share of the market in 2019, whereas the generic drugs segment is anticipated to register a higher CAGR in the market during the forecast period. The projected growth of the market for generic drugs segment is attributed to the factors such as rising demand for low-cost drugs, growing number of FDA-approved generic drugs, rising adoption in emerging nations, and patent expiry of various branded products.

 

Anti - Viral Therapies Market, by Type – 2018 and 2027

Anti - Viral Therapies Market, by Type – 2018 and 2027

Get more information on this report :


 

Mechanism of Action-Based Insights

Based on function, the anti - viral therapies marketis segmented into nucleotide polymerase inhibitor, reverse transcriptase inhibitors, protease inhibitors, and others. The nucleotide polymerase inhibitor segment held the largest share of the market in 2019. However, the reverse transcriptase inhibitors segment is estimated to register the highest CAGR in the market during the forecast period.

 

Application-Based Insights

Based on application, the anti - viral therapies market is segmented into HIV, hepatitis, herpes, virus influenza, and other applications. The HIV segment held the largest share of the market in 2019, and the hepatitis segment is estimated to register the highest CAGR in the market during the forecast period.

 

Strategic Insights

Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios; these strategies help them meet the growing consumer demand. Collaboration is one of the major strategies adopted by the anti - viral therapies market players to enlarge customer base worldwide, which also permits them to maintain their brand name globally.

 

Global Anti - Viral Therapies Market– ByType

  • Generic Drugs
  • Branded Drugs

 

Global Anti - Viral Therapies Market– By Mechanism of Action

 

  • Nucleotide Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others

Global Anti - Viral Therapies Market– By Application

 

  • HIV
  • Hepatitis
  • Herpes
  • Virus Influenza
  • Other Applications

 

Anti - Viral Therapies Market– By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of Asia Pacific
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of Middle East and Africa
  • South and Central America
    • Brazil
    • Argentina
    • Rest of South America

 

Company Profiles

  • AbbVie Inc.
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Aurobindo Pharma
  • AstraZeneca

1.             Introduction

1.1       Scope of the Study

1.2       The Insight Partners Research Report Guidance

1.3       Market Segmentation

1.3.1        Global Anti - Viral Therapies Market – By Type

1.3.2        Global Anti - Viral Therapies Market – By Mechanism of Action

1.3.3        Global Anti-viral therapies market – By Application

1.3.4        Global Anti - Viral Therapies Market – By Geography

2.             Anti-Viral Therapies Market – Key Takeaways

3.             Research Methodology

3.1       Coverage

3.2       Secondary Research

3.3       Primary Research

4.             Global Anti-Viral Therapies – Market Landscape

4.1       Overview

4.2       PEST Analysis

4.2.1        North America – PEST Analysis

4.2.2        Europe – PEST Analysis

4.2.3        Asia Pacific – PEST Analysis

4.2.4        Middle East and Africa (MEA) – PEST Analysis

4.2.5        South and Central America (SCAM) – PEST Analysis

4.3       Expert Opinions

5.             Anti-Viral Therapies Market – Key Market Dynamics

5.1       Market Drivers

5.1.1        Increasing R&D Expenditures in Pharmaceutical Companies

5.1.2        Rising Government Support for Research Activities and Clinical Trials

5.2       Market Restraints

5.2.1        High Cost of Drug Development

5.3       Market Opportunities

5.3.1        Emerging Markets

5.4       Future Trends

5.4.1        Growing Emphasis on Launching Anti-Viral Agents

5.5       Impact analysis

6.             Anti-Viral Therapies Market – Global Analysis

6.1       Global Anti-Viral Therapies Market Revenue Forecast And Analysis

6.2       Global Anti- Viral Therapies Market, By Geography - Forecast And Analysis

6.3       Market Positioning of Key Players

7.             Anti - Viral Therapies Market Analysis – By Type

7.1       Overview

7.2       Anti-viral therapies market Revenue Share, by Type (2019 and 2027)

7.3       Generic Drugs

7.3.1        Overview

7.3.2        Generic Drugs: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

7.4       Branded Drugs

7.4.1        Overview

7.4.2        Branded Drugs: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)

8.             Anti-Viral Therapies Market Analysis – By Mechanism of Action

8.1       Overview

8.2       Anti-Viral Therapies Market Revenue Share, by Mechanism Of Action (2019 and 2027)

8.3       Nucleotide Polymerase Inhibitor

8.3.1        Overview

8.3.2        Nucleotide Polymerase Inhibitor: Anti-Viral Therapies Market – Revenue and Forecast to 2027  (US$ Million)

8.4       Reverse Transcriptase Inhibitors

8.4.1        Overview

8.4.2        Reverse Transcriptase Inhibitors: Anti-Viral Therapies Market – Revenue and Forecast to 2027  (US$ Million)

8.5       Protease Inhibitors

8.5.1        Overview

8.5.2        Protease Inhibitors: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)

8.6       Others

8.6.1        Overview

8.6.2        Others: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)

9.             Anti-Viral Therapies Market Analysis – By Application

9.1       Overview

9.2       Anti-Viral Therapies Market Share, by Application, 2019 and 2027, (%)

9.3       HIV

9.3.1        Overview

9.3.2        HIV: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

9.4       Hepatitis

9.4.1        Overview

9.4.2        Hepatitis: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

9.5       Herpes

9.5.1        Overview

9.5.2        Herpes: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)

9.6       Influenza

9.6.1        Overview

9.6.2        Influenza: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

9.7       Other Applications

9.7.1        Overview

9.7.2        Other Applications: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

10.          Anti-Viral Therapies Market – Geographic Analysis

10.1    North America: Anti-Viral Therapies Market

10.1.1     Overview

10.1.2     North America: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.3     North America: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.1.4     North America: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.1.5     North America: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.1.6     North America: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)

10.1.7     US: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.7.1    US: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.7.2    US: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.1.7.3    US: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.1.7.4    US: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.1.8     Canada: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.8.1    Canada: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.8.2    Canada: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.1.8.3    Canada: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.1.8.4    Canada: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.1.9     Mexico: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.9.1    Mexico: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.9.2    Mexico: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.1.9.3    Mexico: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.1.9.4    Mexico: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.2    Europe: Anti-Viral Therapies Market

10.2.1     Overview

10.2.2     Europe: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (USD Million)

10.2.3     Europe: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.2.4     Europe: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.2.5     Europe: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.2.6     Europe: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)

10.2.7     Germany: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.2.7.1    Germany: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.2.7.2    Germany: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.2.7.3    Germany: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.2.7.4    Germany: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.2.8     UK: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.2.8.1    UK: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.2.8.2    UK: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.2.8.3    UK: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.2.8.4    UK: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.2.9     France: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.2.9.1    France: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.2.9.2    France: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.2.9.3    France: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.2.9.4    France: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.2.10   Spain: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.2.10.1 Spain: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.2.10.2 Spain: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.2.10.3 Spain: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.2.10.4 Spain: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.2.11   Italy: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.2.11.1 Italy: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.2.11.2 Italy: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.2.11.3 Italy: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.2.11.4 Italy: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.3    Asia Pacific: Anti-Viral Therapies Market

10.3.1     Overview

10.3.2     Asia Pacific: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (USD Million)

10.3.3     Asia Pacific: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.3.4     Asia Pacific: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.3.5     Asia Pacific: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.3.6     Asia Pacific: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)

10.3.7     China: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.3.7.1    China: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.3.7.2    China: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.3.7.3    China: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.3.7.4    China: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.3.8     Japan: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.3.8.1    Japan: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.3.8.2    Japan: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.3.8.3    Japan: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.3.8.4    Japan: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.3.9     India: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.3.9.1    India: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.3.9.2    India: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.3.9.3    India: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.3.9.4    India: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.3.10   South Korea: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.3.10.1 South Korea: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.3.10.2 South Korea: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.3.10.3 South Korea: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.3.10.4 South Korea: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.3.11   Australia: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.3.11.1 Australia: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.3.11.2 Australia: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.3.11.3 Australia: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.3.11.4 Australia: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.4    Middle East & Africa: Anti-Viral Therapies Market

10.4.1     Overview

10.4.2     Middle East & Africa: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (US$ Million)

10.4.3     Middle East & Africa: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.4.4     Middle East & Africa Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)

10.4.5     Middle East & Africa Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027  (USD Million)

10.4.6     Middle East & Africa: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)

10.4.7     Saudi Arabia: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.4.7.1    Saudi Arabia: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.4.7.2    Saudi Arabia: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.4.7.3    Saudi Arabia Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)

10.4.7.4    Saudi Arabia Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

10.4.8     UAE: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.4.8.1    UAE: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.4.8.2    UAE: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.4.8.3    UAE Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)

10.4.8.4    UAE Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

10.4.9     South Africa: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.4.9.1    South Africa: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.4.9.2    South Africa: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.4.9.3    South Africa Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)

10.4.9.4    South Africa Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

10.5    South and Central America: Anti-Viral Therapies Market

10.5.1     Overview

10.5.2     South and Central America: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (US$ Million)

10.5.3     South and Central America: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.5.4     South and Central America: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027  (USD Million)

10.5.5     South and Central America: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.5.6     South and Central America: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)

10.5.7     Brazil: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.5.7.1    Brazil: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.5.7.2    Brazil: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.5.7.3    Brazil: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.5.7.4    Brazil: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.5.8     Argentina: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.5.8.1    Argentina: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.5.8.2    Argentina: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.5.8.3    Argentina: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.5.8.4    Argentina: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

11.          Impact of COVID-19 Pandemic on Global Anti-Viral Therapies Market

11.1    North America: Impact Assessment of COVID-19 Pandemic

11.2    Europe: Impact Assessment of COVID-19 Pandemic

11.3    Asia-Pacific: Impact Assessment of COVID-19 Pandemic

11.4    Rest of World: Impact Assessment of COVID-19 Pandemic

12.          Anti-Viral Therapies Market – Industry Landscape

12.1    Overview

12.2    Growth Strategies Done by the Companies in the Market, (%)

12.3    Organic Developments

12.3.1     Overview

12.4    Inorganic Developments

12.4.1     Overview

13.          Company Profiles

13.1    Abbott

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2    AbbVie Inc.

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3    Bristol-Myers Squibb Company

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4    Johnson and Johnson Services, Inc.

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5    Merck & Co., Inc.

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

13.6    Gilead Sciences, Inc.

13.6.1     Key Facts

13.6.2     Business Description

13.6.3     Products and Services

13.6.4     Financial Overview

13.6.5     SWOT Analysis

13.6.6     Key Developments

13.7    GlaxoSmithKline plc.

13.7.1     Key Facts

13.7.2     Business Description

13.7.3     Products and Services

13.7.4     Financial Overview

13.7.5     SWOT Analysis

13.7.6     Key Developments

13.8    AstraZeneca

13.8.1     Key Facts

13.8.2     Business Description

13.8.3     Products and Services

13.8.4     Financial Overview

13.8.5     SWOT Analysis

13.8.6     Key Developments

13.9    Aurobindo Pharma Ltd

13.9.1     Key Facts

13.9.2     Business Description

13.9.3     Products and Services

13.9.4     Financial Overview

13.9.5     SWOT Analysis

13.9.6     Key Developments

13.10 F. HOFFMANN-LA ROCHE LTD.

13.10.1   Key Facts

13.10.2   Business Description

13.10.3   Products and Services

13.10.4   Financial Overview

13.10.5   SWOT Analysis

13.10.6   Key Developments

14.          Appendix

14.1    About The Insight Partners

14.2    Glossary of Terms


LIST OF TABLES

Table 1.             R&D Investments by Major Pharmaceutical Companies

Table 2.             North America Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 3.             North America Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027  (USD Million)

Table 4.             North America Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 5.             US Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 6.             US Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 7.             US Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 8.             Canada Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 9.             Canada Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 10.          Canada Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 11.          Mexico Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 12.          Mexico Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 13.          Mexico Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 14.          Europe Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 15.          Europe Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)

Table 16.          Europe Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 17.          Germany Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 18.          Germany Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 19.          Germany Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 20.          UK Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 21.          UK Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 22.          UK Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 23.          France Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 24.          France Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 25.          France Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 26.          Spain Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 27.          Spain Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 28.          Spain Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 29.          Italy Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 30.          Italy Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 31.          Italy Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 32.          Asia Pacific Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 33.          Asia Pacific Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)

Table 34.          Asia Pacific Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 35.          China Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 36.          China Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 37.          China Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 38.          Japan Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 39.          Japan Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 40.          Japan Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 41.          India Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 42.          India Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 43.          India Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 44.          South Korea Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 45.          South Korea Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027  (USD Million)

Table 46.          South Korea Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 47.          Australia Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 48.          Australia Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 49.          Australia Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 50.          Middle East & Africa Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 51.          Middle East & Africa Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027  (USD Million)

Table 52.          Middle East & Africa Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 53.          Saudi Arabia Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 54.          Saudi Arabia Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027  (USD Million)

Table 55.          Saudi Arabia Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 56.          UAE Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 57.          UAE Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)

Table 58.          UAE Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 59.          South Africa Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 60.          South Africa Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027  (USD Million)

Table 61.          South Africa Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 62.          South and Central America Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 63.          South and Central America Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)

Table 64.          South and Central America Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027  (USD Million)

Table 65.          Brazil Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 66.          Brazil Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)

Table 67.          Brazil Anti-Viral Therapies Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 68.          Argentina Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 69.          Argentina Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)

Table 70.          Argentina Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 71.          Organic Developments Done By Companies

Table 72.          Inorganic Developments Done by Companies

Table 73.          Glossary of Terms, Anti-Viral Therapies Market

 

LIST OF FIGURES

Figure 1.           Anti-Viral Therapies Market Segmentation

Figure 2.           Anti-Viral Therapies Market Segmentation, By Region

Figure 3.           Anti-Viral Therapies Market Overview

Figure 4.           Branded Drugs Segment Held Largest Share of Anti-Viral Therapies Market

Figure 5.           APAC to Show Significant Growth During Forecast Period

Figure 6.           Anti- Viral Therapies Market, by Geography (US$ Million)

Figure 7.           Global Anti -Viral Therapies Market – Leading Country Markets (US$ Million)

Figure 8.           Global Anti-Viral Therapies Market, Industry Landscape

Figure 9.           North America PEST Analysis

Figure 10.        Europe PEST Analysis

Figure 11.        Asia Pacific PEST Analysis

Figure 12.        Middle East and Africa (MEA) PEST Analysis

Figure 13.        South and Central America (SCAM) PEST Analysis

Figure 14.        Anti-Viral Therapies Market Impact Analysis of Driver and Restraints

Figure 15.        Global Anti-Viral Therapies Market – Revenue Forecast And Analysis – 2019- 2027

Figure 16.        Global Anti- Viral Therapies Market – By Geography Forecast and Analysis – 2019- 2027

Figure 17.        Market Positioning Of Key Players In Global Anti- Viral Therapies Market

Figure 18.        Anti-viral therapies market Revenue Share, by Type (2019 and 2027)

Figure 19.        Generic Drugs: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

Figure 20.        Branded Drugs: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)

Figure 21.        Anti-Viral Therapies Market Revenue Share, by Mechanism Of Action (2019 and 2027)

Figure 22.        Nucleotide Polymerase Inhibitor: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

Figure 23.        Reverse Transcriptase Inhibitors: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

Figure 24.        Protease Inhibitors: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)

Figure 25.        Others: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)

Figure 26.        Anti-Viral Therapies Market Share, by Application, 2019 and 2027 (%)

Figure 27.        HIV: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

Figure 28.        Hepatitis: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

Figure 29.        Herpes: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)

Figure 30.        Influenza: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

Figure 31.        Other Applications: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)

Figure 32.        North America: Anti-Viral Therapies Market, by Key Country – Revenue (2019) (USD Million)

Figure 33.        North America Anti-Viral Therapies Market Revenue and Forecast to 2027 (USD Million)

Figure 34.        North America: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)

Figure 35.        US: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 36.        Canada: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 37.        Mexico: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 38.        Europe: Anti-Viral Therapies Market, by Key Country – Revenue (2019) (USD Million)

Figure 39.        Europe Anti-Viral Therapies Market Revenue and Forecast to 2027 (USD Million)

Figure 40.        Europe: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)

Figure 41.        Germany: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 42.        UK: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 43.        France: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 44.        Spain: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 45.        Italy: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 46.        Asia Pacific: Anti-Viral Therapies Market, by Key Country – Revenue (2019) (USD Million)

Figure 47.        Asia Pacific Anti-Viral Therapies Market Revenue and Forecast to 2027 (USD Million)

Figure 48.        China: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 49.        Japan: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 50.        India: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 51.        South Korea: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 52.        Australia: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 53.        Middle East & Africa: Anti-Viral Therapies Market, by Key Country – Revenue (2019) (USD Million)

Figure 54.        Middle East & Africa Anti-Viral Therapies Market Revenue and Forecast to 2027 (USD Million)

Figure 55.        Middle East & Africa: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)

Figure 56.        Saudi Arabia: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 57.        UAE: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 58.        South Africa: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 59.        South and Central America: Anti-Viral Therapies Market, by Key Country – Revenue (2019) (USD Million)

Figure 60.        South and Central America Anti-Viral Therapies Market Revenue and Forecast to 2027 (USD Million)

Figure 61.        South and Central America: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)

Figure 62.        Brazil: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 63.        Argentina: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 64.        Impact of COVID-19 Pandemic in North American Country Markets

Figure 65.        Impact of COVID-19 Pandemic in Europe Country Markets

Figure 66.        Impact of COVID-19 Pandemic in Asia-Pacific Country Markets

Figure 67.        Impact of COVID-19 Pandemic in Rest of World Country Markets

Figure 68.        Growth Strategies Done by the Companies in the Market, (%)

The List of Companies - Anti- Viral Therapies Market

  1. AbbVie Inc.
  2. Abbott
  3. F. Hoffmann-La Roche Ltd
  4. Bristol-Myers Squibb Company
  5. Johnson & Johnson Services, Inc.
  6. Merck and Co., Inc.
  7. Gilead Sciences, Inc.
  8. GlaxoSmithKline plc
  9. Aurobindo Pharma
  10. AstraZeneca
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the anti - viral therapies market.

 

  • Highlights key business priorities in order to assist companies to realign their business strategies.

 

  • The key findings and recommendations highlight crucial progressive industry trends in the global anti - viral therapies market, thereby allowing players across the value chain to develop effective long-term strategies.

 

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

 

  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

 

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPRE00012650
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Frequently Asked Questions

Antiviral therapies is one of the most exciting branches of virology, which involves developing a treatment for viral infections. There are several strategies used to develop antiviral therapy, including direct-acting antivirals that target viral proteins, enzymes, or nucleic acids; passive antibodies that neutralize circulating viruses; drugs that target cellular proteins or processes essential for viral replication.

The factors that are driving growth of the market are growing prevalence of viral diseases, increasing R&D expenditures in pharmaceutical companies and rising government support for research activities and clinical trials. Moreover, emerging markets is expected to offer lucrative opportunities for the growth of the market.

The anti-viral therapies market majorly consists of the players such as AbbVie Inc., Abbott, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, AstraZeneca and Aurobindo Pharma Limited amongst others.

Pricing